Основные параметры
P/E |
18.02 |
P/S |
3.5 |
P/BV |
3.75 |
EV/EBITDA |
8.96 |
EBITDA |
0.6045 |
Цена ао |
102.2 |
Оценка
|
Недооценка
Название |
Значение |
Оценка |
P/S |
3.5 |
2 |
P/BV |
3.75 |
2 |
P/E |
18.02 |
6 |
EV/EBITDA |
8.96 |
8 |
|
|
|
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
11.86 |
4 |
ROE, % |
24.07 |
7 |
|
|
|
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
|
0 |
DSI |
0 |
0 |
|
|
|
|
Долг
Название |
Значение |
Оценка |
Долг/EBITDA |
|
0 |
|
|
|
|
Импульс роста
Название |
Значение |
Оценка |
Рост прибыли, % |
73.01 |
10 |
Рост цены акции, % |
78.61 |
10 |
Рост дивидендов, % |
0 |
0 |
|
|
|
|
События
Название |
Год |
По итогам периода |
Дата закрытия реестра |
Дивиденды, % |
Дивиденды |
Дивиденды |
2016 |
II кв. 2016 |
01.08.2016 |
1.49 |
1.84 |
Основные владельцы
Institutions |
Объем |
Доля, % |
BlackRock Fund Advisors |
8429383 |
2.08 |
AllianceBernstein L.P. |
10188705 |
2.51 |
BlackRock Asset Management Deutschland AG - ETF |
2940447 |
0.73 |
Lyxor Funds Solutions S.A. |
82529 |
0.02 |
Raiffeisen Kapitalanlage GmbH |
500307 |
0.12 |
DWS Investment S.A. (ETF) |
693055 |
0.17 |
HSBC Global Asset Management (France) |
1973055 |
0.49 |
3 Banken-Generali Investment GmbH |
668179 |
0.16 |
Lyxor International Asset Management S.A.S. |
1080962 |
0.27 |
Amundi Asset Management |
1374911 |
0.34 |
UBS Asset Management |
11256804 |
2.78 |
Sparkasse Oberösterreich Kag MBH |
135000 |
0.03 |
Invesco Asset Management Ltd |
2804507 |
0.69 |
Erste Asset Management GmbH |
54953 |
0.01 |
Caixabank Asset Management SGIIC |
916885 |
0.23 |
Security Kapitalanlage AG |
70411 |
0.02 |
East Capital Asset Management S.A. |
222300 |
0.05 |
JP Morgan Asset Management (UK) Ltd |
2155223 |
0.53 |
UBS Asset Management (Americas) Inc |
864182 |
0.21 |
Pioneer Investments Austria GmbH |
490776 |
0.12 |
T. Rowe Price Associates, Inc. |
18676831 |
4.61 |
Schroders Investment Mgt North America |
4137179 |
1.02 |
Fidelity Management & Research Company LLC |
17942121 |
4.42 |
Содержится в ETF
Похожие компании
Описание Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute\u002Femergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4\u002F7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies\u002Fnon-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.